



Testmate Health SA, alongside a consortium of R&D partners that include 3DUniversum and University Hospital of Geneva (HUG) are awarded a €1,37 million non-dilutive grant through the Eurostars Programme funded by the EUREKA countries and European Union.

Epalinges, 7th September 2022, Testmate Health SA, is an early stage Swiss start-up developing at home self-testing kits for common sexually transmitted diseases, enabled by digital health. Today, Testmate Health announced that alongside a consortium of R&D partners that include 3DUniversum and University Hospital of Geneva (HUG) are awarded a €1.37 million non-dilutive grant through the Eurostars Programme funded by the EUREKA countries and European Union.

This funding supports the product development towards clinical validation, the development of the app platform supported by AI, and further clinical validation at the University Hospital of Geneva. This collaboration will kick off on the 1st October 2022.

About Testmate Health

Testmate Health is a seed-stage startup based in the Biôpole, Epalinges. Getting tested for common STDs is an inconvenient process that can only be done in labs and takes days to get a result. Testmate Health has developed an at home urine test for common sexually transmitted diseases that provides results directly at home in minutes, and digitally connects you to a healthcare provider in case of a positive result. This allows people to skip the waiting room by providing an anonymous, convenient option for testing.

Testmate Health combines patented breakthrough innovations in the colorimetric detection of DNA, urine sample preparation techniques & disposable microfluidics to achieve this product. The team's core expertise lies in diagnostic assay development for complex matrices, chemistry, clinical expertise, sexual health, microbiology and is complemented by industry specific medtech expertise.

Testmate Health is supported by Innosuisse, the Swiss Innovation Agency, through which this Eurostars grant is disbursed. Innosuisse has been supporting Testmate Health since its inception through the Initial & Core Coaching Programmes, as well as two grants (the Innosuisse Innovation Cheque and Innovation Project with Implementation Partner).

About Eurostars

The Eurostars program is a funding and support program, aimed at R&D-performing SMEs that wish to exploit the benefits that come with international collaboration. Eurostars applications pass through a highly competitive selection process, being scrutinized by a panel of international research and business experts, to ensure that only the best business ideas and strongest partnerships get the support they need. The consortium consisting of Testmate Health, 3DUniversum & HUG receives a total of €1.37 million non-dilutive grant financed by Innosuisse and RVO Netherlands.

About Hôpitaux Universitaires de Genève (HUG)

Geneva University Hospital (HUG) leads top-level medical research and actively contributes to the progress in medicine through advanced research in medical and healthcare disciplines. The HUG responds to the healthcare needs of a community of 500,000 people. Prof Jacques Schrenzel (MD) is associate professor of medicine at the University of Geneva, Faculty of Medicine; director of the Bacteriology Laboratory and head of the Genomic Research Laboratory (GRL, www.genomic.ch) within HUG. Both laboratories provide a panel of highly specialized tests, and integrate new technologies and new diagnostic assays to clinical care whenever this is relevant for patients or public health. The bacteriology research team conducts clinical, diagnostic and translational investigations, in different fields of microbiology.

In the past, GRL was involved in multiple translational projects:

- qMRSA project (Pfizer research award 2004): Rapid molecular detection of Methicillin-Resistant Staphylococcus aureus (MRSA) directly from clinical swab samples.
- MagRSA project (EC - FP6): Fully automated and integrated microfluidic platform for real-time molecular diagnosis of MRSA
- ZeptoChip: A microarray for rapid bacterial identification from blood culture bottles. A close collaboration between ZeptoSens AG (Witterswil – Switzerland) and GRL
- LAMP-robustness: Evaluation of loop-mediated isothermal amplification reaction for diagnostic applications. The study was funded by FIND and supported by Swiss National Science Foundation (3100A0-116075/1; 3100A0-112370/1). The GRL is highly interested in the development of multiplexed and molecular point of care tests that could be used within the units to improve infection control at HUG and outside.

About 3DUniversum

3DUniversum (3DU) innovates and develops breakthrough AI technology based on cutting-edge academic research. They are a team of pioneering AI experts developing software solutions in the field of deep learning, computer vision and machine learning for a range of industries.

3DUniversum have developed new and commercial software products for renowned companies such as AkzoNobel, Nike, Samsung, Huawei and Talpa. These software solutions are essential for their industrial partners to make a smooth transition into the AI future. In addition to partnering with companies to develop tailor-made AI solutions, their team has developed various innovative product lines including weScan, FairFake and Deeptherapy. Furthermore, 3DU creates custom solutions for (1) eyewear market, (2) healthcare, (3) industrial inspection and (4) retail.

The 3DU team is world leading in AI and specialized in computer vision, machine and deep learning. The uniqueness of 3DUniversum is the combination of AI (academic – MSc's and PhD's) and business (market) developers. The team has in-depth and pioneering knowledge and has written over 250 scientific papers and number of books in the field of computer vision, deep learning and AI.

For further information, please contact Siew-Veena Sahi [at siewveena@testmatehealth.com](mailto:siewveena@testmatehealth.com).